Imatinib, olaparib, olaratumab and regorafenib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.
- Imatinib (Glivec®, Gleevec®, Nibix®, Glimatin®, Imakrebin®, Leutipol®, Tilbaldix®, Mytib® ) is a protein kinase inhibitor and is indicated for the treatment of BCR-ABL positive chronic myeloid leukemia, dermatofibrosarcoma, gastrointestinal stromal tumours and precursor cell lymphoblastic leukemia-lymphoma.
- Olaparib (Lynparza®) is a PARP inhibitor and is indicated for the treatment of ovarian neoplasms.
- Olaratumab (Lartruvo®) is a monoclonal antibody and is indicated for the treatment of soft tissue sarcoma.
- Regorafenib (Stivarga®) is a protein kinase inhibitor and is indicated for the treatment of colorectal neoplasms and gastrointestinal stromal tumours.